Tourmaline Bio’s (TRML) Buy Rating Reiterated at Chardan Capital
Chardan Capital restated their buy rating on shares of Tourmaline Bio (NASDAQ:TRML – Free Report) in a report released on Monday,Benzinga reports. The brokerage currently has a $70.00 price target on the stock. Several other brokerages have also commented on TRML. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price objective on shares […]
Chardan Capital restated their buy rating on shares of Tourmaline Bio (NASDAQ:TRML – Free Report) in a report released on Monday,Benzinga reports. The brokerage currently has a $70.00 price target on the stock. Several other brokerages have also commented on TRML. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price objective on shares […]
